1. Anti-Inflammatory Effects of OxPAPC Involve Endothelial Cell–Mediated Generation of LXA4
- Author
-
Konstantin G. Birukov, Valery N. Bochkov, Yufeng Tian, Fanyong Meng, Taras Afonyushkin, Yunbo Ke, Noureddine Zebda, Olga Oskolkova, Evgeny Berdyshev, Anna A. Birukova, Nicolene Sarich, and Ji Ming Wang
- Subjects
0301 basic medicine ,RHOA ,Endothelium ,Physiology ,Acute Lung Injury ,Inflammation ,Pharmacology ,Lung injury ,Article ,Mice ,03 medical and health sciences ,0302 clinical medicine ,In vivo ,medicine ,Animals ,Humans ,Cells, Cultured ,Mice, Knockout ,biology ,Anti-Inflammatory Agents, Non-Steroidal ,Endothelial Cells ,Lipid signaling ,Lipoxins ,Mice, Inbred C57BL ,Endothelial stem cell ,Treatment Outcome ,030104 developmental biology ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,Immunology ,Phosphatidylcholines ,biology.protein ,Tumor necrosis factor alpha ,medicine.symptom ,Cardiology and Cardiovascular Medicine - Abstract
Rationale: Oxidation of 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphorylcholine (OxPAPC) generates a group of bioactive oxidized phospholipid products with a broad range of biological activities. Barrier-enhancing and anti-inflammatory effects of OxPAPC on pulmonary endothelial cells are critical for prevention of acute lung injury caused by bacterial pathogens or excessive mechanical ventilation. Anti-inflammatory properties of OxPAPC are associated with its antagonistic effects on Toll-like receptors and suppression of RhoA GTPase signaling. Objective: Because OxPAPC exhibits long-lasting anti-inflammatory and lung-protective effects even after single administration in vivo, we tested the hypothesis that these effects may be mediated by additional mechanisms, such as OxPAPC-dependent production of anti-inflammatory and proresolving lipid mediator, lipoxin A4 (LXA4). Methods and Results: Mass spectrometry and ELISA assays detected significant accumulation of LXA4 in the lungs of OxPAPC-treated mice and in conditioned medium of OxPAPC-exposed pulmonary endothelial cells. Administration of LXA4 reproduced anti-inflammatory effect of OxPAPC against tumor necrosis factor-α in vitro and in the animal model of lipopolysaccharide-induced lung injury. The potent barrier-protective and anti-inflammatory effects of OxPAPC against tumor necrosis factor-α and lipopolysaccharide challenge were suppressed in human pulmonary endothelial cells with small interfering RNA–induced knockdown of LXA4 formyl peptide receptor-2 (FPR2/ALX) and in mFPR2 −/− (mouse formyl peptide receptor 2) mice lacking the mouse homolog of human FPR2/ALX. Conclusions: This is the first demonstration that inflammation- and injury-associated phospholipid oxidation triggers production of anti-inflammatory and proresolution molecules, such as LXA4. This lipid mediator switch represents a novel mechanism of OxPAPC-assisted recovery of inflamed lung endothelium.
- Published
- 2017
- Full Text
- View/download PDF